EU approves the new subcutaneous injection of rituximab
-
Last Update: 2014-03-31
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: China Council for the promotion of medicine March 31, 2014 Basel March 28, 2014, Roche announced that the European Commission approved the new subcutaneous injection of rituximab (mabthera) for the treatment of follicular lymphoma and diffuse large B-cell lymphoma This is the second Roche oncology new subcutaneous product approved by the European Union after the approval of Herceptin new subcutaneous injection in September 2013 Sandra horning, Roche's chief medical officer, said, "we believe that subcutaneous injections that take only five minutes to administer can significantly improve the treatment of patients compared to intravenous rituximab injections that take about 2.5 hours." The EU's approval decision is based on key Sabrina research data, which will be published in the Journal of biloba oncology in the near future Roche expects to launch the new hypodermic injection of rituximab to most European markets in 2014 More at: http://
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
